{
    "clinical_study": {
        "@rank": "48679", 
        "acronym": "SEED", 
        "arm_group": [
            {
                "arm_group_label": "Regimen B", 
                "arm_group_type": "Experimental", 
                "description": "Depending on tumor biology testing, subjects assigned to Regimen B will receive:\nTemozolomide 150 mg/m2/dose daily PO on days 1-5, Etoposide 50 mg/m2/dose daily PO on days 1-12, and Everolimus 3 mg/m2/dose daily PO on days 1-28. Cycles will be repeated every 28 days for up to 12 cycles."
            }, 
            {
                "arm_group_label": "Regimen C", 
                "arm_group_type": "Experimental", 
                "description": "Depending on tumor biology testing, subjects assigned to Regimen C will receive:\nTemozolomide 150 mg/m2/dose daily PO on days 1-5, Etoposide 50 mg/m2/dose daily PO on days 1-12, and Erlotinib 85 mg/m2/dose daily PO on days 1-28. Cycles will be repeated every 28 days for up to 12 cycles."
            }, 
            {
                "arm_group_label": "Regimen D", 
                "arm_group_type": "Experimental", 
                "description": "Depending on tumor biology testing, subjects assigned to Regimen D will receive:\nTemozolomide 150 mg/m2/dose daily PO on days 1-5, Etoposide 50 mg/m2/dose daily PO on days 1-12, and Dasatinib 60 mg/m2/dose BID PO on days 1-28. Cycles will be repeated every 28 days for up to 12 cycles."
            }, 
            {
                "arm_group_label": "Regimen A", 
                "arm_group_type": "Experimental", 
                "description": "Depending on tumor biology testing, subjects assigned to Regimen A will receive:\nTemozolomide 150 mg/m2/dose daily PO on days 1-5, Etoposide 50 mg/m2/dose daily PO on days 1-12, and Sorafenib 150 mg/m2/dose BID PO on days 1-28. Cycles will be repeated every 28 days for up to 12 cycles."
            }
        ], 
        "brief_summary": {
            "textblock": "This research study is a Feasibility clinical trial.  In this trial, researchers are trying\n      to figure out whether a medication can be chosen based on rapid testing done on tumor\n      tissue.  Information from a feasibility or pilot trial will hopefully help researchers plan\n      larger trials in the future to determine the effect of this therapy."
        }, 
        "brief_title": "Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors", 
        "completion_date": {
            "#text": "June 2020", 
            "@type": "Anticipated"
        }, 
        "condition": "Recurrent Childhood Brain Tumor", 
        "condition_browse": {
            "mesh_term": "Brain Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "This research study will assign a specific drug treatment based on lab tests performed on\n      the participant's tumor from tumor tissue taken from a biopsy done when he/she was first\n      diagnosed or if taken when he/she relapsed or progressed. All participants will get\n      Temozolomide and Etoposide to start.  Then depending on review of the participant's tumor\n      tissue he/she will also receive one of the following: Sorafenib, Everolimus, Erlotinib, or\n      Dasatinib.\n\n      The purpose of this research study is to learn about the feasibility of obtaining and using\n      information from studies done on tumor tissue in order to help make treatment decisions for\n      patients with relapsed or refractory pediatric brain tumors.  The investigators also want to\n      find out the effects this therapy has on the participant and the participant's brain tumor."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Patients must have histological confirmation of a brain tumor at diagnosis or relapse for\n        all tumors.\n\n        There must be documented progression or recurrence of disease by MRI imaging or CSF\n        studies since completion of last tumor-directed medical therapy. Patients may have had\n        surgical resection or radiation of tumor, and need not have measurable or evaluable\n        disease at study entry.\n\n        Patient's current disease state must be one for which there is no known curative therapy.\n\n        Age greater than 1 month and less than 30 years at the time of enrollment.\n\n        BSA greater than 0.3 m2 at the time of enrollment.\n\n        Karnofsky >/= 50% for patients > 16 years of age, and Lansky >/= 50% for patients </= 16\n        years of age.\n\n          -  Neurologic deficits in patients with CNS tumors must have been relatively stable for\n             a minimum of 7 days.\n\n          -  Patients who are unable to walk because of paralysis, but who are up in a wheelchair,\n             will be considered ambulatory for the purpose of assessing the performance score.\n\n        Adequate bone marrow function including:\n\n          -  ANC > 750\n\n          -  Platelet count > 100,000/uL without platelet transfusion within the past 7 days\n\n        Adequate renal function defined as creatinine within normal range for age or calculated\n        GFR > 100 ml/min/1.73 m2.\n\n        Adequate liver function defined as Bilirubin < 1.5 x upper limit of normal and ALT < 2.5 x\n        upper limit of normal.\n\n        Adequate CNS function:\n\n          -  Patients with known seizure disorder must have seizures adequately controlled with\n             non-enzyme inducing antiepileptic medications\n\n          -  No increase in steroid dose within the past 7 days.\n\n        Patients must have fully recovered from the acute toxic effects of all prior chemotherapy,\n        immunotherapy, or radiotherapy:\n\n          -  Myelosuppressive chemotherapy: Must not have received within 3 weeks of    entry onto\n             this study (6 weeks if prior nitrosourea).\n\n          -  Hematopoietic growth factors: At least 7 days since the completion of therapy with a\n             growth factor, 14 days for longacting (e.g. PEG-filgrastim)\n\n          -  Biologic (anti-neoplastic agent): At least 7 days or 3 half-lives (whichever is\n             longer) since the completion of therapy with a biologic agent.\n\n          -  Radiation therapy: \u2265 12 weeks must have elapsed from craniospinal radiation; \u2265 2\n             weeks must have elapsed from focal radiation.\n\n          -  Surgery: > 3 weeks from major surgery. If recent craniotomy, adequate wound healing\n             must be determined by neurosurgical team prior to starting study therapy.\n\n          -  Autologous Stem Cell Transplant or Rescue: No evidence of active graft vs. host\n             disease and \u2265 4 weeks must have elapsed.\n\n        All patients and/or a legal guardian must sign institutionally approved written informed\n        consent document.\n\n        Exclusion Criteria:\n\n        Patients who are breastfeeding, pregnant or refuse to use an effective form of birth\n        control are excluded. Abstinence is considered an effective form of birth control.\n\n        Patients with uncontrolled infection are excluded.\n\n        Patients with known bleeding disorders or more than punctate intratumoral hemorrhage are\n        excluded.\n\n        Patients receiving other anti-neoplastic agents are excluded.\n\n        Patients on enzyme-inducing anticonvulsive agents are excluded.\n\n        Patients requiring strong CYP3A4 inducers or inhibitors are excluded.\n\n        Patients requiring anticoagulation or with uncontrolled bleeding are excluded.\n\n        Patients on steroids for symptom management must be on a stable dose over the 7 days prior\n        to study enrollment.\n\n        Patients within 1 year of allogeneic stem cell transplant, patients with active GVHD or\n        requiring immunosuppression are excluded."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "30 Years", 
            "minimum_age": "1 Month"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02015728", 
            "org_study_id": "SC-9006"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Regimen B", 
                    "Regimen C", 
                    "Regimen D", 
                    "Regimen A"
                ], 
                "description": "Tumor biology studies will be performed in a CLIA-approved clinical pathology laboratory using standard procedures. Immunohistochemical (IHC) testing will be performed on formalin fixed tumor obtained at the time of diagnosis and/or relapse. Results will be interpreted by a qualified pediatric pathologist and will be scored on a scale of 0 to 4+ commenting on both percentage of positive cells and intensity of staining. Results will further be reported as a binary result (positive/negative). If more than one tumor specimen is available from different surgical procedures (e.g. initial diagnosis and relapse), the results from the relapse specimen will be prioritized.  Results will determine kinase inhibitor treatment arm assignment which will be administered in addition to the \"best available\" combination of low-dose oral cytotoxic agents, including temozolomide and etoposide.", 
                "intervention_name": "Tumor biology testing", 
                "intervention_type": "Device", 
                "other_name": [
                    "IHC Testing", 
                    "Immunohistochemical Screening", 
                    "Immunohistochemical Test", 
                    "Tumor Biology Testing", 
                    "Tumor Markers"
                ]
            }, 
            {
                "arm_group_label": [
                    "Regimen B", 
                    "Regimen C", 
                    "Regimen D", 
                    "Regimen A"
                ], 
                "description": "Temozolomide combined with Etoposide is considered the \"best available\" combination of low-dose oral cytotoxic agents for patients with refractory or recurrent CNS tumors.", 
                "intervention_name": "Temozolomide", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Temodar", 
                    "Temodal", 
                    "Temcad"
                ]
            }, 
            {
                "arm_group_label": [
                    "Regimen B", 
                    "Regimen C", 
                    "Regimen D", 
                    "Regimen A"
                ], 
                "description": "Etoposide combined with Temozolomide is considered the \"best available\" combination of low-dose oral cytotoxic agents for patients with refractory or recurrent CNS tumors.", 
                "intervention_name": "Etoposide", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Etopophos", 
                    "Vepesid"
                ]
            }, 
            {
                "arm_group_label": "Regimen A", 
                "description": "Sorafenib is a broad-spectrum kinase inhibitor.", 
                "intervention_name": "Sorafenib", 
                "intervention_type": "Drug", 
                "other_name": "Nexavar"
            }, 
            {
                "arm_group_label": "Regimen B", 
                "description": "Everolimus is an mTOR pathway inhibitor.", 
                "intervention_name": "Everolimus", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Zortress", 
                    "Certican"
                ]
            }, 
            {
                "arm_group_label": "Regimen C", 
                "description": "Erlotinib is a tyrosine kinase inhibitor of the ERBB family of proteins.", 
                "intervention_name": "Erlotinib", 
                "intervention_type": "Drug", 
                "other_name": "Tarceva"
            }, 
            {
                "arm_group_label": "Regimen D", 
                "description": "Dasatinib is a broad spectrum SRC inhibitor.", 
                "intervention_name": "Dasatinib", 
                "intervention_type": "Drug", 
                "other_name": "Sprycel"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Etoposide", 
                "Etoposide phosphate", 
                "Temozolomide", 
                "Sorafenib", 
                "Sirolimus", 
                "Dacarbazine", 
                "Everolimus", 
                "Erlotinib", 
                "Dasatinib"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Refractory", 
            "Recurrent", 
            "Brain", 
            "Tumor", 
            "Pediatric", 
            "Biologically Targeted Therapy", 
            "Sorafenib", 
            "Everolimus", 
            "Erlotinib", 
            "Dasatinib", 
            "Temozolomide", 
            "Etoposide"
        ], 
        "lastchanged_date": "May 7, 2014", 
        "location": {
            "contact": {
                "email": "sarah.leary@seattlechildrens.org", 
                "last_name": "Sarah ES Leary, MD", 
                "phone": "206-987-2106"
            }, 
            "contact_backup": {
                "email": "kimberly.starr@seattlechildrens.org", 
                "last_name": "Kimberly A Starr, BA, CCRP", 
                "phone": "206-884-7274"
            }, 
            "facility": {
                "address": {
                    "city": "Seattle", 
                    "country": "United States", 
                    "state": "Washington", 
                    "zip": "98105"
                }, 
                "name": "Seattle Children's"
            }, 
            "investigator": [
                {
                    "last_name": "Sarah ES Leary, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Julie Park, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Douglas Hawkins, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "James Olson, MD, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Blythe Thomson, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Jessica Pollard, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Rebecca Johnson, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Eric Chow, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Phoenix Ho, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Rebecca Gardner, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Abby Rosenberg, MD, MS", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Abraham Fong, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Corrine Hoeppner, ARNP", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "The Feasibility of Selecting Patient-Specific Biologically Targeted Therapy With Sorafenib, Everolimus, Erlotinib or Dasatinib for Pediatric Patients With Refractory Or Recurrent Brain Tumors", 
        "overall_contact": {
            "email": "sarah.leary@seattlechildrens.org", 
            "last_name": "Sarah ES Leary, MD", 
            "phone": "206-987-2106"
        }, 
        "overall_contact_backup": {
            "email": "kimberly.starr@seattlechildrens.org", 
            "last_name": "Kimberly A. Starr, BA, CCRP", 
            "phone": "206-884-7274"
        }, 
        "overall_official": {
            "affiliation": "Seattle Children's", 
            "last_name": "Sarah ES Leary, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "It will be considered feasible to obtain individual biologic testing if at least 80% of patients receive results of biology studies within two weeks of study enrollment.\nIt will be considered feasible to treat patients based on biologic testing if at least and 50% of patients who consent for biology testing start therapy with one of four regimens within four weeks of study enrollment.", 
            "measure": "Feasibility", 
            "safety_issue": "No", 
            "time_frame": "3 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02015728"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Seattle Children's Hospital", 
            "investigator_full_name": "Sarah Leary", 
            "investigator_title": "Assistant Professor of Pediatrics", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Efficacy endpoint for patients with evaluable or measurable disease will be best objective response (CR, PR, SD or PD) measured by MRI imaging.", 
                "measure": "Efficacy", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "description": "Survival endpoints will be estimated including time to progression as well as progression-free and overall survival rates at the 6 month, 1 year and 2 year time point from start of study treatment.", 
                "measure": "Survival", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "description": "Toxicity endpoints will be descriptive and include grading of patient toxicity according to the National Cancer Institute common terminology criteria for adverse events (CTCAE version 4.0). This study is not intended or powered to compare toxicity between treatment arms.  The tolerability of selected therapy with the addition of a kinase inhibitor will be described for all patients as a group.", 
                "measure": "Toxicity", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }
        ], 
        "source": "Seattle Children's Hospital", 
        "sponsors": {
            "collaborator": {
                "agency": "Cures Within Reach", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Seattle Children's Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}